相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: A post-hoc analysis
Matti Aapro et al.
BREAST (2011)
Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients
Maria Aparecida Nagai et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
Barry Mirtsching et al.
CLINICAL BREAST CANCER (2011)
Docetaxel-based combination therapy for castration-resistant prostate cancer
M. D. Galsky et al.
ANNALS OF ONCOLOGY (2010)
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Christopher Lobo et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
SPARC (Osteonectin) in Breast Tumors of Different Histologic Types and Its Role in the Outcome of Invasive Ductal Carcinoma
Yi-Hsuan Hsiao et al.
BREAST JOURNAL (2010)
A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer
Andre Robidoux et al.
CLINICAL BREAST CANCER (2010)
Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
Alison K. Conlin et al.
CLINICAL BREAST CANCER (2010)
Nanoparticle albumin-bound (nab (TM))-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
Javier Cortes et al.
EJC SUPPLEMENTS (2010)
SPARC microeniironment signature (SNIP) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative e metastatic breast cancer (TNMBC).
K. L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
V. Roy et al.
ANNALS OF ONCOLOGY (2009)
Docetaxel-related side effects and their management
Jackie Baker et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2009)
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
William J. Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy
Valentina Guarneri et al.
ONCOLOGIST (2009)
Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
Neil P. Desai et al.
ANTI-CANCER DRUGS (2008)
The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
Osvaldo L. Podhajcer et al.
CANCER AND METASTASIS REVIEWS (2008)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J. Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials
Michele De Laurentiis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor a therapy
Lisa D. Volk et al.
NEOPLASIA (2008)
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
Joanne L. Blum et al.
CLINICAL BREAST CANCER (2007)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Albumin-bound paclitaxel: a next-generation taxane
William J. Gradishar
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
DW Nyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
NK Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
MC Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes
G Watkins et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Novel markers for poor prognosis in head and neck cancer
D Chin et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
AJ ten Tije et al.
CLINICAL PHARMACOKINETICS (2003)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Role of formulation vehicles in taxane pharmacology
L van Zuylen et al.
INVESTIGATIONAL NEW DRUGS (2001)
Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats
Nicolas Authier et al.
NEUROTOXICITY RESEARCH (2001)
分享论文
